Trandolapril and verapamil slow release in the treatment of hypertension: A dose-response assessment with the use of a multifactorial trial design

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 6, 1997, Pages 361-374

  Levine, Jon H ^a   Applegate, William B ^b  

^a Clinical Research Associates Inc   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Hypertension; Multifactorial trial; Trandolapril; Verapamil

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; VERTIGO;

EID: 0030757395     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80095-1     Document Type: Article

References (29)

1. Chobanian AV. Antihypertensive therapy in evolution. NEJM. 1986;314:1701-1702.
2. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment. Am Heart J. 1995;130:359-366.
3. MacConnachie AM, Maclean D. Low dose combination antihypertensive therapy. Additional efficacy without additional adverse effects? Drug Saf. 1995;12:85-90.
4. Materson BJ, Reda DJ, Cushman WC, Henderson WG. Results of combination antihypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J Hum Hypertens. 1995; 9:791-796.
5. Waeber B, Brunner HR. Main objectives and new aspects of combination treatment of hypertension. J Hypertens Suppl. 1995;13(Suppl 2):S15-S19.
6. Kaplan NM. Guidelines for the treatment of hypertension: An American view. Fifth Joint National Committee. J Hypertens Suppl. 1995;13(Suppl 2):S113-S117.
7. Romero R, Castellote E, Ocon J, Wagner B. Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. J Cardiovasc Pharmacol. 1995;26:114-118.
8. Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens. 1995;8(5:Pt 1):461-466.
9. Chrysant SG, Fox AA, Stimpel M. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. Am J Hypertens. 1995;8(4:Pt 1):418-421.
10. Holwerda K, Hoogma RP, Oldenbroeck C, et al. Efficacy and safety of benazepril plus hydrochlorothiazide versus benazepril alone in hypertensive patients unresponsive to benazepril monotherapy. Clin Ther. 1994;16:942-951.
11. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med. 1996;156: 278-285.
12. Soffer BA, Wright JT Jr, Pratt JH, et al. The effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995;26:112-117.
13. Frishman WH, Landau A, Cretkovic A. Combination drug therapy with calcium blockers in the treatment of systemic hypertension. J Clin Pharmacol. 1993;33:752-755.
14. Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/ Amlodipine Study Group. J Clin Pharmacol. 1995;35:1060-1066.
15. Wiseman LR, McTavish D. Trandolapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994;48:71-90.
16. Arner P, Wade A, Engfeldt P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol. 1994;23(Suppl 4):S44-S49.
17. Cong Duc LN, Brunner HR. Trandolapril in hypertension: Overview of a new angiotensin-converting enzyme inhibitor. Am J Cardiol. 1992;70:27D-34D.
18. Cubeddu LX, Aranda J, Singh B, et al. A comparison of verapamil and propranolol for the initial treatment of hypertension: Racial differences in response. JAMA. 1986;256:2214-2221.
19. Jain AK, McMahon FG. 24-hour blood pressure response to two slow-release verapamil formulations in patients with mild to moderate hypertension. Cardiovasc Rev Rep. 1993; 14:45-51.
20. Saunders E, Weir MR, Kong W, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-1713.
21. Fixed combination prescription drugs for humans (21 CFR 300.50). Code of Federal Regulations. April 1, 1996.
22. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med. 1994;154:1461-1468.
23. Hung HM, Ng TH, Chi GY. Response surface and factorial designs for combination antihypertensive drugs. Drug Inform J. 1990;24:371-378.
24. Frohlich ED, Grim C, Labarthe DR, et al. Recommendations for human blood pressure determination by sphygmomanometers. Hypertension. 1988;11:210A-222A.
25. Snapinn SM. Evaluating the effects of combination therapy. Stat Med. 1987;6:657-665.
26. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. Hypertension. 1995;26:124-130.
27. Halperin AK, Kirsten M, Gross M, et al. Verapamil and propranolol in essential hypertension. Clin Pharmacol Ther. 1984;36:750-758.
28. Messerli F, Frishman WH, Elliot WJ, for the Trandolapril Study Group. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens. In press.
29. Smith DHG, Neutel JM, Black HR, et al. Once-daily monotherapy with trandolapril in the treatment of hypertension. J Hum Hypertens. 1996;10:129-134.